Advertisement

Ads Placeholder
Loading...

Sequana Medical NV

SEQUA.BREURONEXT
Healthcare
Medical - Devices
0.50
-0.02(-4.40%)
U.S. Market opens in 7h 37m

Sequana Medical NV Fundamental Analysis

Sequana Medical NV (SEQUA.BR) shows weak financial fundamentals with a PE ratio of -0.37, profit margin of 0.00%, and ROE of 1.24%. The company generates N/A in annual revenue with weak year-over-year growth of -85.12%.

Key Strengths

Cash Position38.23%
PEG Ratio0.03

Areas of Concern

ROE1.24%
Operating Margin0.00%
Current Ratio0.20
We analyze SEQUA.BR's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -34.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-34.2/100

We analyze SEQUA.BR's fundamental strength across five key dimensions:

Efficiency Score

Weak

SEQUA.BR struggles to generate sufficient returns from assets.

ROA > 10%
-3.56%

Valuation Score

Excellent

SEQUA.BR trades at attractive valuation levels.

PE < 25
-0.37
PEG Ratio < 2
0.03

Growth Score

Weak

SEQUA.BR faces weak or negative growth trends.

Revenue Growth > 5%
-85.12%
EPS Growth > 10%
0.00%

Financial Health Score

Moderate

SEQUA.BR shows balanced financial health with some risks.

Debt/Equity < 1
-1.06
Current Ratio > 1
0.20

Profitability Score

Weak

SEQUA.BR struggles to sustain strong margins.

ROE > 15%
124.12%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is SEQUA.BR Expensive or Cheap?

P/E Ratio

SEQUA.BR trades at -0.37 times earnings. This suggests potential undervaluation.

-0.37

PEG Ratio

When adjusting for growth, SEQUA.BR's PEG of 0.03 indicates potential undervaluation.

0.03

Price to Book

The market values Sequana Medical NV at -0.49 times its book value. This may indicate undervaluation.

-0.49

EV/EBITDA

Enterprise value stands at -0.34 times EBITDA. This is generally considered low.

-0.34

How Well Does SEQUA.BR Make Money?

Net Profit Margin

For every $100 in sales, Sequana Medical NV keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $1.24 in profit for every $100 of shareholder equity.

1.24%

ROA

Sequana Medical NV generates $-3.56 in profit for every $100 in assets, demonstrating efficient asset deployment.

-3.56%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.47 in free cash annually.

$-0.47

FCF Yield

SEQUA.BR converts -46.09% of its market value into free cash.

-46.09%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.37

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.03

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.49

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-1.06

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.20

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

1.24

vs 25 benchmark

ROA

Return on assets percentage

-3.56

vs 25 benchmark

ROCE

Return on capital employed

0.48

vs 25 benchmark

How SEQUA.BR Stacks Against Its Sector Peers

MetricSEQUA.BR ValueSector AveragePerformance
P/E Ratio-0.3728.54 Better (Cheaper)
ROE124.12%738.00% Weak
Net Margin0.00%-43982.00% (disorted) Weak
Debt/Equity-1.060.34 Strong (Low Leverage)
Current Ratio0.202806.01 Weak Liquidity
ROA-355.86%-14624.00% (disorted) Weak

SEQUA.BR outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Sequana Medical NV's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-96.33%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-0.16%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

62.88%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ